Eli Lilly faces a long-term GLP-1 patent cliff
The long-term valuation of Eli Lilly is threatened by the inevitable transition of GLP-1 weight-loss drugs to cheap generics.
The argument
The speaker argued that because consumers have zero brand loyalty to drug manufacturers and simply want the cheapest option, Eli Lilly's massive cash flows will dry up once patents expire. While Lilly has staged successive product iterations, insurers and consumers will eventually opt for cheap, generic versions of older GLP-1s like Ozempic.
The thesis, stress-tested
✓ What validates it
- ✓The launch of low-cost generic semaglutide in key global markets
- ✓Insurance companies shifting coverage mandates to favor generic alternatives over branded GLP-1s
▸ Risks discussed
- ▸Lilly could successfully defend its market share through complex, hard-to-replicate manufacturing processes
- ▸Newer, highly superior formulations could successfully delay consumer migration to older generics
Hear it yourself
"Lilly has brilliantly staged each GLP to come out one after another in this really smart way. But at some point, the consumers and the insurers say, I don't need SuperGLP Max Pro Plus."
00:00 / 00:12
AFFILIATE LINK · ZORTIX MAY EARN A COMMISSION · NEVER A RECOMMENDATION TO TRADE